Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.42 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 2/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | PRKX | P51817 | 2/20 | 0.42 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.42 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534399 | 0.76 | PLK1 (0.40) | PLK1CDC7PLK4DAPK3ROCK2 | |
| SCHEMBL7013832 | 0.72 | PLK1 (0.47) | PLK1CDC7PLK4DAPK3ROCK2 | |
| SCHEMBL7534291 | 0.71 | PDE2A (0.41) | PDE2ACES2CES1 | |
| SCHEMBL7011585 | 0.70 | PLK1 (0.40) | PLK1CDC7PLK4DAPK3ROCK2 | |
| SCHEMBL7887005 | 0.69 | CHEK1 (0.47) | PLK1CDC7PLK4DAPK3ROCK2 | |
| SCHEMBL8639166 | 0.69 | CHEK1 (0.47) | PLK1CDC7PLK4DAPK3ROCK2 | |
| SCHEMBL2304585 | 0.68 | ACP3 (0.56) | CES2CES1 | |
| SCHEMBL8176841 | 0.66 | CA1 (0.49) | PLK1CDC7PLK4DAPK3ROCK2 | |
| SCHEMBL7731888 | 0.65 | ACACB (0.55) | PDE2A | |
| SCHEMBL13683329 | 0.65 | ACACB (0.55) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003529532-A | — | — | 2003-10-07 | — | — | JP | claimed |
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-28 | — | — | US | claimed |
| US-6465523-B1 | TREATMENT OF SMOOTH MUSCLE CONTRACTION DISORDERS SUCH AS URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-15 | — | — | US | claimed |
| EP-1135365-A1 | 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2000034230-A1 | 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-28 | — | — | US | disclosed |
| US-6465523-B1 | TREATMENT OF SMOOTH MUSCLE CONTRACTION DISORDERS SUCH AS URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-15 | — | — | US | disclosed |
| US-6462059-B1 | TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION; URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, AND CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-08 | — | — | US | disclosed |
| US-6376555-B1 | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | KCNN3, KCNJ2, KCNE1 | PLK1 3801/4885CDC7 2405/4885PLK4 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.